1-2 of 2
Arjan A. van de Loosdrecht
Close
Sort by
Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4267–4277.
https://doi.org/10.1182/bloodadvances.2020002846
Published: 2020
Includes: Supplemental data
Journal Articles

Guideline-based indicators for adult patients with myelodysplastic syndromes

Kristina Stojkov, Tobias Silzle, Georg Stussi, David Schwappach, Juerg Bernhard, David Bowen, Jaroslav Čermák, Avinash G. Dinmohamed, Corien Eeltink, Sabrina Eggmann, Pierre Fenaux, Ulrich Germing, Manuel Haschke, Eva Hellstrom-Lindberg, Monika Heger, Arjan A. van de Loosdrecht, Jakob Passweg, Michael Pfeilstöcker, Uwe Platzbecker, Luca Malcovati, António Medina de Almeida, Moshe Mittelman, Christine Morgenthaler, David P. Steensma, Valeria Santini, Reinhard Stauder, Argiris Symeonidis, Sämi Schär, Charlotte Maddox, Theo de Witte, Julia Bohlius, Nicolas Bonadies
Journal: Blood Advances
Blood Adv (2020) 4 (16): 4029–4044.
https://doi.org/10.1182/bloodadvances.2020002314
Published: 2020
Includes: Supplemental data